MedTrace Logo

EGCG for Hepatocellular Carcinoma Chemoprevention

NCT06015022 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-05

No results posted yet for this study

Summary

This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.

Conditions

  • Cirrhosis, Liver

Interventions

DRUG

Epigallocatechin gallate (EGCG)

EGCG is a green tea-derived catechin

OTHER

Placebo

Placebo in the same capsule with the experimental agent (EGCG).

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Yujin Hoshida, MD, PhD · UT Southwestern

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015022 on ClinicalTrials.gov